| Biomarker ID | 1098 |
| PMID | 23574937 |
| Year | 2013 |
| Biomarker | miR-423-3p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated with High Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- sequence-specific DNA binding; RNA binding; posttranscriptional regulation of gene expression; anatomical structure morphogenesis; sequence-specific double-stranded DNA binding |
| Experiment | Gleason Score < 7 Vs Gleason Score ≥ 8 |
| Type of Biomarker | Prognostic |
| Cohort | 25 PCa patients with treatment-naive localized disease (localized PCa) and 25 patients with metastatic castration resistant PCa and a rising PSA (mCRPC patients) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.002 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-423-3p |